PHARMACOKINETICS AND CLINICAL EFFICACY OF CEFOTIAM HEXETIL

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement6; pp. 527 - 534
• Main Authors: OKANO, MANABU, GOBARA, MASARU, AKINO, HIRONOBU, ISOMATSU, YUKISHIGE, MURANAKA, KOJI, KANIMOTO, YUSUKE, SHIMIZU, YASUO, KAWADA, YUKIMICHI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1988
• Subjects: Cefotiam hexetil
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement6_527

We studied the pharmacokinetics, clinical efficacy and safety of cefotiam hexetil (CTM-HE), a new oral cephem antibiotic, in urinary tract infections. First, serum and urinary levels of cefotiam after a single oral administration of 200 mg of CTM-HE were determined in 5 healthy volunteers. A maximum serum level of 2.66μg/ml was achieved 2 hours after administration and the average serum half-life was 0.67 hours. The average urinary recovery rate was 33.7% within 8 hours. Next, 4 patients with acute uncomplicated and 8 with chronic complicated cystitis were treated. Excellent clinical response was obtained in all 4 patients with acute uncomplicated cystitis treated with 300 mg per day of CTM-HE for 3 days. Of the 8 patients with chronic complicated cystitis treated with 600 mg per day of CTM-HE for 5 to 7 days, excellent or moderate response was obtained in 3. No clinical adverse reactions were observed in any of the 12 patients treated. From the results obtained in this study, we conclude that CTM-HE is as well tolerated as other oral cephems and effective in the treatment of mild or moderate urinary tract infections.